Regeneron Pharma (REGN) PT Raised to $388 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold—if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
S&P keeps New Year's rally alive, Dow eases
January 8, 2018 7:52 AM ESTBy Sinead Carew
(Reuters) - The S&P 500 extended its winning streak for 2018 on Monday although its advance slowed to a crawl as the healthcare and financial sectors weighed and investors awaited the start of the quarterly earnings season.
The healthcare sector was the S&P's worst performer on Monday, and investors were cautious about pouring money into bank stocks before the companies kick off the fourth-quarter earnings season later this week.
"We had a big move last week and everyone knows earnings is coming up. People don't want to chase too much further... More
Sanofi (SNY), Regeneron (REGN) to accelerate, expand investment for cemiplimab and dupilumab development programs
January 8, 2018 7:03 AM EST
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. Both of these breakthrough therapies have the potential to benefit a number of different patient populations and this strategic investment will enable the companies to evaluate cemiplimab and dupilumab in broad clinical development programs.... More
